Other ECM components such as Versican (VCAN) correlate with CD8+ T cell exclusion and tumor-intrinsic β-catenin nuclear translocation in colorectal cancer, while proteolysis of VCAN into versikine reverses this effect through the recruitment of CD103+ MHCIIhi BATF3+ DCs via IRF8 (106). This evidence concerns the gene VCAN and neoplasm.